Skip to main content
Premium Trial:

Request an Annual Quote

Rheonix Receives SBIR Grant to Finish Development of HIV Assay

NEW YORK (GenomeWeb) – Rheonix announced today that it has received a $1.5 million Small Business Innovation Research Phase II grant from the National Institutes of Health to continue development of its fully automated self-confirming assay for the simultaneous detection of HIV/AIDS antibodies and viral RNA in a single specimen.

The system is designed to simplify HIV testing and eliminate the need for multiple visits by a patient to healthcare providers.

Under a now-completed SBIR Phase I grant, the company developed a proof-of-concept test based on its automated Rheonix Chemistry and Reagent Device platform, which performs sample extraction, purification, amplification, and detection.

The company said that the Phase II grant, which runs for 18 months, will be used to develop a commercial-ready test that will be deployed in the developing world.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.